The PKC inhibitor ruboxistaurin can stabilize the eGFR and reduce urinary albumin in DKD patients, indicating the protective effect of PKC inhibition on delaying DKD progression 59. The gene discussed is PRRT2; the disease is diabetic kidney disease.